Kiri

Programme

Wed 23 Oct

07:30 Arrival and registration 07:30 to 08:30

BREAK

08:30 Official opening 08:30 to 09:00

Auditorium I

PLENARY SESSION

09:00 Meeting the needs of service users and service providers Plenary 1 09:00 to 10:30

Auditorium I

PLENARY SESSION

e-poster session day 1 09:00 to 18:20

Digital kiosks

E-POSTER SESSION

e-short communication session day 1 09:00 to 18:20

Digital kiosks

E-SHORT COMMUNICATION SESSION

10:30 Coffee break 10:30 to 10:50

BREAK

10:50 Cannabis legalisation in Canada and the US: policy variation, state of the evidence and ideas for future research 10:50 to 12:20

Auditorium I

Advances in drug treatment 10:50 to 12:20

Auditorium II

ORAL PRESENTATION SESSION

Innovative health approaches 10:50 to 12:20

Auditorium III

ORAL PRESENTATION SESSION

MAJOR SESSION

Sex, gender and diversity in drugs 10:50 to 12:20

Auditorium IV

ORAL PRESENTATION SESSION

Advancing addiction research: global perspectives and collaborative initiatives 10:50 to 12:20

Auditorium VI

ORAL PRESENTATION SESSION

Lives at risk: mental health and substance use 10:50 to 12:20

Auditorium VII

ORAL PRESENTATION SESSION

Prevalence of opioids and related harms 10:50 to 12:20

Auditorium VIII

ORAL PRESENTATION SESSION

Mechanisms and outcomes in substance use prevention among youth 10:50 to 12:20

Room 5A

ORAL PRESENTATION SESSION

Gambling: work-related, financial, and criminological issues 10:50 to 12:20

Room 5B

ORAL PRESENTATION SESSION

Building addiction workforce capacity 10:50 to 12:20

Room 5C

ORAL PRESENTATION SESSION

Treatment of alcohol use disorder 10:50 to 12:20

Room 1.05

SHORT COMMUNICATION SESSION

Support for recovery 10:50 to 12:20

Room 1.07

SHORT COMMUNICATION SESSION

Alcohol: policy and harm reduction 10:50 to 12:20

Room 1.08

SHORT COMMUNICATION SESSION

Closed session ECR Programme — Scientific writing 10:50 to 12:20

Room 1.10

WORKSHOP

Evaluation of drug consumption rooms: guidance step by step 10:50 to 12:20

Room 1.15

WORKSHOP

12:20 Lunch break 12:20 to 13:20

BREAK

13:20

Enhancing access to harm reduction services in community and prisons: experiences of translating policy into practice and scaling interventions 13:20 to 14:50

Auditorium I

MAJOR SESSION

Alcohol use in the young 13:20 to 14:50

Auditorium II

ORAL PRESENTATION SESSION

Neuroscience and cognition 13:20 to 14:50

Auditorium III

SHORT COMMUNICATION SESSION

Legal shifts and their Impact on drug use and sentencing 13:20 to 14:50

Auditorium IV

ORAL PRESENTATION SESSION

Drug policy and the criminal legal system 13:20 to 14:50

Auditorium VI

ORAL PRESENTATION SESSION

Tobacco, mental health and other substance use 13:20 to 14:50

Auditorium VII

ORAL PRESENTATION SESSION

Gender and substance use 13:20 to 14:50

Auditorium VIII

ORAL PRESENTATION SESSION

Substance use interventions in youth 13:20 to 14:50

Room 5A

ORAL PRESENTATION SESSION

Neurocognitive processes in behavioural addictions 13:20 to 14:50

Room 5B

ORAL PRESENTATION SESSION

Learning from Africa: workforce development, enhancement and support 13:20 to 14:50

Room 5C

ORAL PRESENTATION SESSION

Alcohol use disorder: clinical biology and epidemiology 13:20 to 14:50

Room 1.05

SHORT COMMUNICATION SESSION

Meetings the needs of women who use drugs or alcohol 13:20 to 14:50

Room 1.06

SHORT COMMUNICATION SESSION

Challenge of measuring use and impact of cannabinoids 13:20 to 14:50

Room 1.07

ORAL PRESENTATION SESSION

Methods and measurement 13:20 to 14:50

Room 1.08

SHORT COMMUNICATION SESSION

The peer model: the critical role of ethics in efficacy 13:20 to 14:50

Room 1.15

WORKSHOP

14:50

Break 14:50 to 15:00

BREAK

15:00 Challenges in community- based prevention 15:00 to 16:30

Auditorium I

MAJOR SESSION

Alcohol use from brief intervention to harm reduction 15:00 to 16:30

Auditorium II

ORAL PRESENTATION SESSION

The recovery journey 15:00 to 16:30

Auditorium III

ORAL PRESENTATION SESSION

Infectious diseases in people who inject drugs 15:00 to 16:30

Auditorium IV

ORAL PRESENTATION SESSION

Measuring drug market phenomenon 15:00 to 16:30

Auditorium VI

ORAL PRESENTATION SESSION

Substance use and psychosis 15:00 to 16:30

Auditorium VII

ORAL PRESENTATION SESSION

The growing threat of synthetic drugs – developments and responses in North America and Europe 15:00 to 16:30

Auditorium VIII

ORAL PRESENTATION SESSION

Surveillance of drug- related morbidity and mortality 15:00 to 16:30

Room 5A

ORAL PRESENTATION SESSION

Assessment of behavioural addictions 15:00 to 16:30

Room 5B

ORAL PRESENTATION SESSION

Inequalities and needs of migrant groups 15:00 to 16:30

Room 5C

ORAL PRESENTATION SESSION

Responses to behavioural addictions 15:00 to 16:30

Room 1.05

SHORT COMMUNICATION SESSION

Quality in addictions work systems 15:00 to 16:30

Room 1.06

ORAL PRESENTATION SESSION

Problematic gambling and gaming 15:00 to 16:30

Room 1.07

SHORT COMMUNICATION SESSION

Conceptualising health and harms 15:00 to 16:30

Room 1.08

SHORT COMMUNICATION SESSION

WAVE Cine Video contest session 1: Showcasing innovative science and services 15:00 to 16:30

Room 1.09

VIDEO CONTEST

Trauma and addiction - developing skills in the screening of traumatic experiences in addiction care 15:00 to 16:30

Room 1.10

WORKSHOP

LEGO® SERIOUS PLAY® Hands-On Workshop on Optimizing Workplace and Well-Being for Workers in Addiction Fields 15:00 to 16:30

Room 1.15

WORKSHOP

16:30 Coffee break 16:30 to 16:50

BREAK

16:50 The EUFAS-EAR European Addiction Research Award 16:50 to 18:20

Auditorium I

MAJOR SESSION

Strengthening quality in substance use disorders treatment 16:50 to 18:20

Auditorium II

ORAL PRESENTATION SESSION

NPS: trends, concerns and response strategies 16:50 to 18:20

Auditorium III

ORAL PRESENTATION SESSION

Drug use trends 16:50 to 18:20

Auditorium IV

ORAL PRESENTATION SESSION

Decriminalisation and alternatives to arrest 16:50 to 18:20

Auditorium VI

ORAL PRESENTATION SESSION

Understanding interrelationships: mental health and substance use 16:50 to 18:20

Auditorium VII

ORAL PRESENTATION SESSION

Psychedelics 1 16:50 to 18:20

Auditorium VIII

ORAL PRESENTATION SESSION

Novel and contextual approaches in prevention 16:50 to 18:20

Room 5A

ORAL PRESENTATION SESSION

Opioid treatment 1 16:50 to 18:20

Room 5B

ORAL PRESENTATION SESSION

Motivations for use 16:50 to 18:20

Room 5C

ORAL PRESENTATION SESSION

Hepatitis C, HIV, and other drug related harms 16:50 to 18:20

Room 1.05

SHORT COMMUNICATION SESSION

Opioids: trends, use and treatments 16:50 to 18:20

Room 1.06

SHORT COMMUNICATION SESSION

Capacity-building through competencies for the substance use workforce 16:50 to 18:20

Room 1.10

WORKSHOP

Showcasing AI and digital workforce support 16:50 to 18:20

Room 1.15

WORKSHOP

18:20 Break 18:20 to 18:30

BREAK

18:30 Why are we not doing better at reducing drug- related deaths? 18:30 to 19:30

Auditorium I

BIG DEBATE

Thu 24 Oct

09:00

Synthetic opioids and psychedelics: new opportunities & new challenges for clinical practice Plenary session 2 09:00 to 10:30

Auditorium I

PLENARY SESSION

Expert knowledge elicitation to complement and enhance data collection and monitoring efforts. 09:00 to 10:30

Room 1.10

WORKSHOP

Workshop on conducting drug research in prison: Challenges and key recommendations from the European experience 09:00 to 10:30

Room 1.15

WORKSHOP

e-poster session day 2 09:00 to 18:20

Digital kiosks

E-POSTER SESSION

e-short communication session day 2 09:00 to 18:20

Digital kiosks

E-SHORT COMMUNICATION SESSION

10:30 Coffee break 10:30 to 10:50

BREAK

10:50 International collaboration to understand and address the co-occurrence of addiction with ADHD and autism spectrum disorders 10:50 to 12:20

Auditorium I

MAJOR SESSION

Predicting the future: biomarkers for progression of alcohol use disorder 10:50 to 12:20

Auditorium II

ORAL PRESENTATION SESSION

Opioid treatment 2 10:50 to 12:20

Auditorium III

ORAL PRESENTATION SESSION

Opioid Agonist Treatment: novel formulations and challenges 10:50 to 12:20

Auditorium IV

ORAL PRESENTATION SESSION

Evidence informed drug and alcohol policy 10:50 to 12:20

Auditorium VI

ORAL PRESENTATION SESSION

Emerging drug harms, DCRs and other responses 10:50 to 12:20

Auditorium VII

SHORT COMMUNICATION SESSION

The challenges of the digital era: an interdisciplinary investigation of screen time and social media. 10:50 to 12:20

Auditorium VIII

MAJOR SESSION

Innovative methods for understanding drug markets and policy 10:50 to 12:20

Room 5A

ORAL PRESENTATION SESSION

Young people and comorbidity - alcohol, gambling and mental health 10:50 to 12:20

Room 5B

ORAL PRESENTATION SESSION

Workers reaching marginalised groups 10:50 to 12:20

Room 5C

ORAL PRESENTATION SESSION

Challenges, threats, and opportunities in addiction publishing today 10:50 to 12:20

Room 1.05

ORAL PRESENTATION SESSION

Natural language processing for addiction research: a practical primer 10:50 to 12:20

Room 1.06

WORKSHOP

EU research funding opportunities 10:50 to 12:20

Room 1.07

WORKSHOP

Contemporary issues 10:50 to 12:20

Room 1.08

ORAL PRESENTATION SESSION

Closed session ECR Programme — An introduction to theory in qualitative research 10:50 to 12:20

Room 1.10

WORKSHOP

Back-casting exercise on peer-support workforce development 10:50 to 12:20

Room 1.15

WORKSHOP

12:20 Lunch break 12:20 to 13:20

BREAK

13:20

New opportunities for informing clinical practice and policy development in the area of behavioural addictions 13:20 to 14:50

Auditorium I

MAJOR SESSION

EUFAS General assembly 13:20 to 14:50

Auditorium II

PLENARY SESSION

Novel neurobiology - cannabis, cognition and craving 13:20 to 14:50

Auditorium III

ORAL PRESENTATION SESSION

Understanding drug- related deaths 13:20 to 14:50

Auditorium IV

ORAL PRESENTATION SESSION

Conceptual frameworks for studying drug policy 13:20 to 14:50

Auditorium VI

ORAL PRESENTATION SESSION

Young people, mental health and substance use 13:20 to 14:50

Auditorium VII

ORAL PRESENTATION SESSION

Nitazene-related fatal and non-fatal toxicity in Europe: hospital emergency perspective 13:20 to 14:50

Auditorium VIII

ORAL PRESENTATION SESSION

Public health and safety impacts of cannabis legalization in Canada: five years in review 13:20 to 14:50

Room 5A

ORAL PRESENTATION SESSION

Pregnancy, drug use and care 13:20 to 14:50

Room 5B

ORAL PRESENTATION SESSION

Co-creating robust systems with workers 13:20 to 14:50

Room 5C

ORAL PRESENTATION SESSION

Understanding harm reduction: economic, social, and health perspectives 13:20 to 14:50

Room 1.05

SHORT COMMUNICATION SESSION

European prevention curriculum: increasing the use of evidence- based prevention 13:20 to 14:50

Room 1.06

SHORT COMMUNICATION SESSION

Women's realities of drug use 13:20 to 14:50

Room 1.08

ORAL PRESENTATION SESSION

WAVE Cine Video contest session 2: Sharing insightful lived experience 13:20 to 14:50

Room 1.09

VIDEO CONTEST

Scenarios for the future of addictions fields by 2040 13:20 to 14:50

Room 1.10

WORKSHOP

Writing for 'addiction' journals for early career researchers with DEPP Editors-in-Chief 13:20 to 14:50

Room 1.15

WORKSHOP

14:50 Break 14:50 to 15:00

BREAK

15:00 New perspectives: AI as a tool to support the addictions workforce 15:00 to 16:30

Auditorium I

MAJOR SESSION

Alcohol epidemiology: social inequalities 15:00 to 16:30

Auditorium II

ORAL PRESENTATION SESSION

NPS: Pharmacological Characterization and Substance Analysis 15:00 to 16:30

Auditorium III

ORAL PRESENTATION SESSION

Hepatitis C testing and treatment 15:00 to 16:30

Auditorium IV

ORAL PRESENTATION SESSION

Cannabis legalisation — models and impacts 15:00 to 16:30

Auditorium VI

ORAL PRESENTATION SESSION

How can treatment be a better experience? 15:00 to 16:30

Auditorium VII

ORAL PRESENTATION SESSION

The hepatitis C endgame: Science, Policy, Politics 15:00 to 16:30

Auditorium VIII

MAJOR SESSION

Protective and risk factors in drug prevention 15:00 to 16:30

Room 5A

ORAL PRESENTATION SESSION

Policy issues in gambling 15:00 to 16:30

Room 5B

ORAL PRESENTATION SESSION

A unique care model for inpatient addictions and tri-morbidity within an acute UK hospital 15:00 to 16:30

Room 5C

ORAL PRESENTATION

Novel psychoactive substances and latest drug trends in Asia and Pacific countries 15:00 to 16:30

Room 1.05

ORAL PRESENTATION

From genes to brains 15:00 to 16:30

Room 1.06

SHORT COMMUNICATION SESSION

SESSION SESSION

City insights: creating a collaborative network for city-level monitoring of drug trends and harm reduction 15:00 to 16:30

Room 1.07

WORKSHOP

Drug trends: experiences from Brazil, the Netherlands, Portugal, and Spain 15:00 to 16:30

Room 1.08

ORAL PRESENTATION SESSION

How to train an addiction specialist? 15:00 to 16:30

Room 1.10

WORKSHOP

How to respond to real- time drug alerts in European countries ? 15:00 to 16:30

Room 1.15

WORKSHOP

16:30 Coffee break 16:30 to 16:50

BREAK

16:50 How can the voices of people with lived experience, clients and communities impacted by drug use better inform clinical practice, research and the policy agenda? 16:50 to 17:50

Auditorium I

BIG DEBATE

Alcohol and gender issues 16:50 to 18:20

Auditorium II

ORAL PRESENTATION SESSION

Mixed methods for understanding drug use 16:50 to 18:20

Auditorium III

ORAL PRESENTATION SESSION

Viral hepatitis among people who inject drugs 16:50 to 18:20

Auditorium IV

ORAL PRESENTATION SESSION

Alcohol use among the elderly 16:50 to 18:20

Auditorium VI

ORAL PRESENTATION SESSION

Substance use and mental health in treatment settings 16:50 to 18:20

Auditorium VII

ORAL PRESENTATION SESSION

Misuse of medicines 16:50 to 18:20

Auditorium VIII

ORAL PRESENTATION SESSION

New research on alcohol and tobacco policy 16:50 to 18:20

Room 5A

ORAL PRESENTATION SESSION

Hospital-based treatments 16:50 to 18:20

Room 5B

ORAL PRESENTATION SESSION

From old to new: changes in drug use 16:50 to 18:20

Room 5C

ORAL PRESENTATION SESSION

Behavioural addictions, prevention and theory 16:50 to 18:20

Room 1.05

SHORT COMMUNICATION SESSION

Newly regulated markets, managing harms, treatment & advocating for reform 16:50 to 18:20

Room 1.06

SHORT COMMUNICATION SESSION

Internet, smartphones and social media use 16:50 to 18:20

Room 1.07

SHORT COMMUNICATION SESSION

ScaleUp: Options for scalable psychosocial and pharmacological treatment of stimulant use disorder 16:50 to 18:20

Room 1.08

ORAL PRESENTATION SESSION

A two-phased augmentation/interventio n extension of Claremont’s media-based prevention education model 16:50 to 18:20

Room 1.10

WORKSHOP

Toolkit to Deal with Female Drug User Victims of Gender-Based Violence 16:50 to 18:20

Room 1.15

WORKSHOP

17:50 EUDA presentation 17:50 to 18:20

Auditorium I

MAJOR SESSION

18:20

Break 18:20 to 18:30

BREAK

18:30 EUDA launch networking dinner (for all conference participants) 18:30 to 21:30

BREAK

Fri 25 Oct

09:00 Joining the dots: the relationship between substance use and other health conditions Plenary session 3 09:00 to 10:30

Auditorium I

PLENARY SESSION

A comparative discussion on the role, challenges, and opportunities for addiction nurses within Europe 09:00 to 10:30

Room 1.15

WORKSHOP

e-poster session day 3 09:00 to 14:50

Digital kiosks

E-POSTER SESSION

e-short communication session day 3 09:00 to 14:50

Digital kiosks

E-SHORT COMMUNICATION SESSION

10:30 Coffee break 10:30 to 10:50

BREAK

10:50 The ripple effect: International developments in the opioid market and their potential implications for European public health and security 10:50 to 12:20

Auditorium I

MAJOR SESSION

Alcohol: interventions and up-to-date technologies 10:50 to 12:20

Auditorium II

ORAL PRESENTATION SESSION

Gaming and social media use 10:50 to 12:20

Auditorium III

ORAL PRESENTATION SESSION

Intentional and non- intentional drug-related deaths 10:50 to 12:20

Auditorium IV

ORAL PRESENTATION SESSION

Psychedelics 2 10:50 to 12:20

Auditorium VI

ORAL PRESENTATION SESSION

Trauma and substance use 10:50 to 12:20

Auditorium VII

ORAL PRESENTATION SESSION

Unravelling the nexus: understanding drug- related violence across Europe 10:50 to 12:20

Auditorium VIII

ORAL PRESENTATION SESSION

Drugs checking services 10:50 to 12:20

Room 5A

ORAL PRESENTATION SESSION

Online monitoring 10:50 to 12:20

Room 5B

ORAL PRESENTATION SESSION

Substance use and treatment needs across European prisons 10:50 to 12:20

Room 5C

ORAL PRESENTATION SESSION

Emerging challenges in drug markets: monitoring, measurement & impacts 10:50 to 12:20

Room 1.05

SHORT COMMUNICATION SESSION

Gaming and health 10:50 to 12:20

Room 1.06

SHORT COMMUNICATION SESSION

Support for the addiction workforce 10:50 to 12:20

Room 1.07

ORAL PRESENTATION SESSION

How can cannabis policy goals inform the development of evaluation indicators? 10:50 to 12:20

Room 1.08

WORKSHOP

WAVE Cine Video contest session 3: Journeys through addiction science and lived experience 10:50 to 12:20

Room 1.09

VIDEO CONTEST

Closed session ECR Programme — EU research funding opportunities 10:50 to 12:20

Room 1.10

WORKSHOP

Intimate partner violence perpetration: The ADVANCE-Digital Programme for men 10:50 to 12:20

Room 1.15

WORKSHOP

12:20 Lunch break 12:20 to 13:20

BREAK

13:20 Findings from The Lancet Public Health Commission on Gambling: protecting the public from gambling harms 13:20 to 14:50

Auditorium I

ORAL PRESENTATION SESSION

Alcohol and other drug policies in the work setting – a perspective on European developments 13:20 to 14:50

Auditorium II

ORAL PRESENTATION SESSION

Young people and drugs 13:20 to 14:50

Auditorium III

ORAL PRESENTATION SESSION

Overdose prevention 13:20 to 14:50

Auditorium IV

ORAL PRESENTATION SESSION

Addressing diverse treatment needs 13:20 to 14:50

Auditorium VI

ORAL PRESENTATION SESSION

Substance use and mental health in prison settings 13:20 to 14:50

Auditorium VII

ORAL PRESENTATION SESSION

Regulating cannabis supply policies in Europe: navigating the long road to change 13:20 to 14:50

Auditorium VIII

ORAL PRESENTATION SESSION

Prevention and addiction in underrepresented groups 13:20 to 14:50

Room 5A

ORAL PRESENTATION SESSION

Impact of drug policy on drug production & markets 13:20 to 14:50

Room 5B

ORAL PRESENTATION SESSION

Holistic care for mental well-being 13:20 to 14:50

Room 1.05

SHORT COMMUNICATION SESSION

Future of opioid markets in Europe: Foresight approaches 13:20 to 14:50

Room 1.10

WORKSHOP

Research into practice: The implementation and evaluation of alcohol assertive outreach treatment in England 13:20 to 14:50

Room 1.15

WORKSHOP

14:50 Break 14:50 to 15:00

BREAK

15:00 Future paradigms for drug markets and drug policies? Closing session 15:00 to 16:40

Auditorium I

PLENARY SESSION

16:40 Closing ceremony 16:40 to 16:50

Auditorium I

PLENARY SESSION

Source URL:https://www.lisbonaddictions.eu/lisbon-addictions-2024/programme

.

Your trip LVFPQ8Booking ref: CheckMyTrip App

Document Issue Date: 10 October 2024

.

.

Traveler Ms Kelli Ilisson Agency WRIS NARVA MNT 7D 10117 EE-20124 TALLINN

Telephone 372 6129 130

Fax 372 6129 129

Email [email protected] .

Reisil esilekerkivate probleemide korral palume helistada Wris 24/7 telefonil: +372 53309747 In case of emergency please contact Wris Travel Agency under +372 53309747 .

Tuesday 22 October 2024

Finnair AY 1016 (Operated by Nordic Reg For Finnair)

Departure 22 October 11:45 Tallinn, (Lennart Meri) (+)

Arrival 22 October 12:15 Helsinki, (Helsinki Vantaa) (+)

Duration 00:30 (Non stop)

Booking status Confirmed

Class Economy (K)

1 Piece(s) for Ms Kelli IlissonBaggage allowance

Check in completed by 11:00

Equipment ATR 72

No meal serviceFlight meal

.

Tuesday 22 October 2024

Check-in

Finnair AY 1739

Departure 22 October 12:50 Helsinki, (Helsinki Vantaa) (+)

Arrival 22 October 15:40 Lisbon, (Airport) (+) Terminal: 1

Duration 04:50 (Non stop)

Booking status Confirmed

Class Economy (K)

1 Piece(s) for Ms Kelli IlissonBaggage allowance

Check in completed by 12:05

Equipment AIRBUS A321 (SHARKLETS)

Food and beverages for purchaseFlight meal

.

Friday 25 October 2024

Page 1 of 2

Check-in

Finnair AY 1740

Departure 25 October 16:35 Lisbon, (Airport) (+) Terminal: 1

Arrival 25 October 23:15 Helsinki, (Helsinki Vantaa) (+)

Duration 04:40 (Non stop)

Booking status Confirmed

Class Economy (H)

1 Piece(s) for Ms Kelli IlissonBaggage allowance

Check in completed by 15:50

Equipment AIRBUS A321 (SHARKLETS)

Food and beverages for purchaseFlight meal

.

Saturday 26 October 2024

Finnair AY 1035 (Operated by Nordic Reg For Finnair)

Departure 26 October 00:20 Helsinki, (Helsinki Vantaa) (+)

Arrival 26 October 00:55 Tallinn, (Lennart Meri) (+)

Duration 00:35 (Non stop)

Booking status Confirmed

Class Economy (H)

1 Piece(s) for Ms Kelli IlissonBaggage allowance

Check in completed by 23:35

Equipment EMBRAER 190

No meal serviceFlight meal

.

Ticket details E-ticket AY 105-5416125664 for Ms Kelli Ilisson

.

General Information Wris valvetelefon 37253309747 Wris travel agency emergency no 37253309747 Palun kontrollige viisa vajalikkust,reisidokumendi kehtivust!

.

Ecological information Calculated average CO2 emission is 531.77 kg/person

Source: ICAO Carbon Emissions Calculator

http://www.icao.int/environmental-protection/CarbonOffset/Pages/default.aspx .

Airline Booking Reference(s) AY (Finnair): LVFPQ8

.

Data Protection Notice: Your personal data will be processed in accordance with the applicable carrier’s privacy policy and, if your booking is made via a reservation system provider (“GDS”), with its privacy policy. These are available at http://www.iatatravelcenter.com/privacy or from the carrier or GDS directly. You should read this documentation, which applies to your booking and specifies, for example, how your personal data is collected, stored, used, disclosed and transferred. (applicable for interline carriage). .

.

Page 2 of 2

POLIISI NUMBER: 90028076 VÄLJAANDMISE AEG: 10.10.2024

1/4

POLIIS NR 90028076

KINDLUSTUSVÕTJA: SOTSIAALKINDLUSTUSAMET, 70001975 Endla tn 8, Kesklinna linnaosa, Tallinn, Harju maakond

KINDLUSTUSANDJA: Salva Kindlustuse AS reg.kood 10284984 Pärnu mnt 16 10141 Tallinn, tel +372 6800 500, faks +372 6800 501, e-post [email protected]

POLIISI TURUSTAJA: Vivika Rüü, AKTSIASELTS WRIS, tel: +372 6129126, e-post: [email protected] KINDLUSTUSAGENT: AKTSIASELTS WRIS

KINDLUSTATUD ESE KINDLUSTUSTOODE KINDLUSTUSPERIOOD KINDLUSTUSMAKSE 1. Tervis, Reisitõrge, Pagas Reisikindlustus 22.10.2024 - 25.10.2024 30,18 EUR

Kokku 30,18 EUR

1. REISIKINDLUSTUS

KINDLUSTATUD ESE: Tervis, Reisitõrge, Pagas

RISKIANDMED Kehtivuspiirkond: Euroopa k.a Maroko,

Tuneesia, Iisrael, AÜE, Ukraina, Valgevene, Venemaa Euroopa osa, Gruusia, Aserbaidžaan, Armeenia

Perekindlustus: Ei

KINDLUSTUSSUMMAD KINDLUSTATU KOHTA Tervis (RK-20 p. 4, 9: KÜ-23 p. 14, 15, 18): 100 000 EUR Reisitõrge (RK-20 p. 5, 9: KÜ-23 p. 14, 15, 18): 1 750 EUR Pagas (RK-20 p. 6, 9: KÜ-23 p. 14, 15, 18): 400 EUR Rendiauto omavastutus (RK-20 p. 7, 9: KÜ-23 p. 14, 15, 18): Kindlustushuvi puudub Tsiviilvastutus (RK-20 p. 8, 9: KÜ-23 p. 14, 15, 18): Kindlustushuvi puudub

TERVISEKINDLUSTUSE KINDLUSTUSKAITSE LAIENDUSED Kõrgendatud riskiga tegevus ja füüsiline töö: Ei

REISITÕRKE KINDLUSTUSKAITSE LAIENDUSED Reisitõrke looduskatastroof, terrorism ja rahvarahutus:

Ei Ürituse ärajäämine: Ei

Streik, maksevõimetus: Ei

KINDLUSTATUD ISIK: Kelli Ilisson, 49502146020 Reisi ärajäämise kindlustuskaitse alguskuupäev: 14.10.2024 00:00

KINDLUSTUSPERIOOD: 22.10.2024 00:00 - 25.10.2024 23:59

SOODUSTUS: Kindlustusmakse sisaldab kampaaniasoodustust 11,27 EUR (Salva pagasikindlustus kuni 400 € tasuta;Riigiasutused).

ERITINGIMUSED: Golfireisi eritingimus Erinevalt punktis 6.4.8 ja 6.4.9 toodust on golfivarustus kindlustatud kogu pagasi kindlustussumma ulatuses.

COVID-19 haigestumisega seotud tervisekindlustuse kaitse Tervisekindlustuse alusel hüvitatakse COVID-19 (sealhulgas COVID-19 mutatsioonidest ja variatsioonidest lähtuva) haigestumise tõttu välismaal tekkinud ravikulud (kulud diagnostikale, ravimitele,haiglaravile) kuni summani 200 000 eurot. Juhul kui kindlustuslepingusse märgitud tervisekindlustuse kindlustussumma on väiksem kui 200 000 eurot, on hüvitatavate COVID-19 ravikulude maksimaalne suurus piiratud tervisekindlustuse kindlustussummaga. Samuti katame lisakulutused majutusele karantiini sattumise korral ning vajadusel uute tagasisõidupiletite maksumuse kuni 2000 eurot eeldusel, et kindlustatul on meditsiiniliselt kinnitatud COVID-19 haigestumine.

COVID-19 haigestumisega seotud reisitõrke kaitse Hüvitame kasutamata reisipaketi maksumuse juhul, kui kindlustatul diagnoositakse COVID-19 haigestumine pärast reisi ärajäämise kindlustuskaitse kehtivuse algust ning reisimine on seega vastunäidustatud.

Kindlustatu peab COVID-19 haigestumise tõendama arstitõendiga, kiirtesti tulemust kindlustusandja tõendina ei aktsepteeri.

Kindlustuskaitse algus Käesolev poliis kehtib vaid nende kindlustatute osas, kes 22.10.2024 alustavad oma reisi Eesti Vabariigist. Juhul kui kindlustatu viibib 22.10.2024 juba välismaal, siis tema kindlustuskaitse algab 25.10.2024.

POLIISI NUMBER: 90028076 VÄLJAANDMISE AEG: 10.10.2024

2/4

TINGIMUSTE TÄPSUSTUS Reisi ärajäämise (5.1.1) kindlustusjuhtumiks ei loeta punktis 5.2.7 loetletud põhjuseid, mille tõttu jääb kindlustatud isikul ära planeeritud reis. Reisitõrke kindlustuse punkti 5.4.3 alusel ei hüvitata eralennuki kasutamise kulusid.

Reisi ärajäämise kindlustuskaitse alguskuupäev Erinevalt poliisil märgitud Reisi ärajäämise kindlustuskaitse alguskuupäevast hakkab Reisi ärajäämise kindlustuskaitse kehtima koheselt peale kindlustuspoliisi väljastamist, kui kindlustusleping on ostetud samal päeval kui reisiteenus, mille ärajäämise riski kindlustusleping katab.

TÜÜPTINGIMUSED: Reisikindlustuse tingimused (RKT-20.03) Salva Kindlustuse AS Kindlustuse Üldtingimused (KÜ-23) Kindlustuslepingule kohalduvate tüüptingimuste- ja isikuandmete töötlemise põhimõtetega on võimalik tutvuda Salva Kindlustuse AS kodulehel www.salva.ee.

POLIISI KINDLUSTUSMAKSE

KINDLUSTUSMAKSE KOKKU: 30,18 EUR MAKSEOSADE ARV: 1 TASUMISE KORD: Osamakse suurus: Tasumise tähtaeg:

30,18 EUR 10.10.2024

TINGIMUSED

KINDLUSTUSLEPINGU LÕPETAMINE: Kindlustuslepingu lõpetamise tingimused on toodud võlaõigusseaduses ning kindlustuspoliisil viidatud tüüptingimustes.

KINDLUSTUSLEPINGULE KOHALDATAV ÕIGUS: Käesolevale kindlustuslepingule kohaldatakse Eesti õigust.

VAIDLUSTE LAHENDAMISE KORD: Kindlustuslepingust tulenevad vaidlused lahendatakse lepingus nimetatud tüüptingimuste ja Eesti Vabariigi õigusaktide alusel. Kindlustusvaidluste kohtuväliseks lahendamiseks on õigus pöörduda Eesti Kindlustusseltside Liidu juures tegutseva kindlustusvaidluste lepitusorgani poole aadressil Mustamäe tee 46, 10621, Tallinn (lisateave www.eksl.ee/et/lepitusorgan). Enne lepitusmenetlust tuleb vaidlusküsimuses esitada nõue kindlustusandjale ja anda kindlustusandjale võimalus nõudele vastata. Kindlustusvaidlused, mille suhtes ei ole saavutatud kokkulepet, lahendatakse Harju Maakohtus.

KAHJUJUHTUMIST TEAVITAMINE: Salva Kindlustuse koduleht: www.salva.ee/et/kahjukasitlus või Pärnu mnt 16 10141 Tallinn tel 6800 500 e-post [email protected]

KAHJUJUHTUMIST TEATAMISE TÄHTAEG: Kindlustusvõtja või temaga võrdsustatud isik peab kahju toimumisest, selle iseloomust ja suurusest kindlustusandjat informeerima kirjalikult või kirjalikku taasesitamist võimaldavas vormis viivitamatult alates kahjujuhtumist teadasaamisest, hiljemalt kahjujuhtumile järgneval esimesel tööpäeval.

KINDLUSTUSLEPINGU SÕLMIMINE: Kindlustusleping jõustub esimese kindlustusmakse laekumisele järgnevast päevast, juhul kui ei ole kokku lepitud teisiti. Juhul kui kindlustusmakse on tasutud tähtaegselt, algab kindlustuskaitse kindlustusperioodil märgitud kindlustusperioodi esimesel kuupäeval. Kui esimene kindlustusmakse laekub hiljem kui 15 päeva arvates kindlustuspoliisile märgitud makse tasumise tähtpäevast, siis kindlustusleping ei jõustu ning kindlustusmakse kuulub tagastamisele. Kindlustusandjal ei ole kohustust maksta kindlustushüvitist nende kindlustusjuhtumite eest, mis toimusid enne kindlustuslepingu jõustumist. Kindlustuslepingu mistahes muudatus jõustub poliisile märgitud kuupäevale järgneval päeval, juhul kui ei ole kokku lepitud teisiti. Esimese kindlustusmakse tasumisega kinnitab kindlustusvõtja, et ta on kätte saanud kõik kindlustuslepingule kohalduvad kindlustustingimused, ta nõustub poliisil ja tingimustes oleva teabega ning kindlustusvõtjat, kindlustatut, kindlustatud eset ja kindlustusriski puudutavad andmed on õiged. Juhul kui poliisi sisu kaldub kõrvale kindlustusvõtja poolt edastatud teabest, peab kindlustusvõtja sellest kindlustusandjale teatama enne arve tasumist. Koos poliisiga väljastatakse kindlustusvõtjale arve esimese kindlusmakse tasumise kohta. Pooled on kokku leppinud, et arve edastatakse ainult elektroonilises vormis.

KINDLUSTATU KOHUSTUS: Kindlustusjuhtumi korral on kindlustatu nõus oma tervist puudutava meditsiinilise teabe, sh eelneva meditsiinilise seisundi kohta informatsiooni väljastamisega Salva Kindlustusele.

SIDEVAHENDI ABIL SÕLMITUD LEPINGUST TAGANEMINE: Tarbijast kindlustusvõtja võib sidevahendi abil sõlmitud kindlustuslepingust taganeda põhjust avaldamata 14 päeva jooksul. Taganemise tähtaeg algab kindlustuslepingu sõlmimise päevale järgnevast päevast. Taganemise õigus ei kehti pikenevate kindlustuslepingute suhtes.

KINDLUSTUSLEPINGU ANDMED: Kindlustusleping on sõlmitud kindlustusvõtja poolt kindlustusandjale edastatud teabe alusel kindlustusobjekti ja kindlustushuvi kohta. Kindlustusvõtja kinnitab, et käesoleva kindlustuslepingu sõlmimise eelselt on kindlustusandja selgitanud välja tema kindlustushuvi, tutvustanud kindlustusandja poolt pakutavaid kindlustuslahendusi ning kindlustusleping vastab kindlustusvõtja kindlustushuvile. Vahendustasu suuruseks käesoleva kindlustuslepingu sõlmimisel on 30%. Käesoleva kindlustuslepingu vahendanud kindlustusagent (AKTSIASELTS WRIS, Narva mnt 7D, Kesklinna linnaosa, Tallinn, Harju maakond, Eesti) on kantud kindlustusvahendajana Finantsinspektsiooni kodulehel avaldatud kindlustusagentide nimekirja (https://www.fi.ee/et /kindlustus/kindlustusvahendajad/kindlustus-0/kindlustusvahendajad). Nimetatud kodulehele on märgitud agendi poolt vahendatavad Salva Kindlustuse AS kindlustusliigid. Agent kinnitab, et tema poolt Salva Kindlustuse AS nimel kindlustuslepingu sõlmimiseks väljastatud kindlustuspakkumine või kindlustuslepingu sõlmimine on kooskõlas talle Salva Kindlustuse AS poolt antud volitusega. Salva Kindlustuse AS on väljastanud agendile kinnituse, et vastutab tema vahendustegevuse eest Salva Kindlustuse AS nimel. Järelevalvet kindlustusagendi tegevuse üle teostab Finantsinspektsioon, Sakala tn 4 15030. Kindlustuslepingust tulenevaid vaidlusi lahendab kohtueelselt Eesti Kindlustusseltside Liidu juures tegutsev lepitusorgan (https://www.lkf.ee/et /lepitusorgan).

POLIISI NUMBER: 90028076 VÄLJAANDMISE AEG: 10.10.2024

3/4

KINDLUSTUSVÕTJA TEAVITAMISE KOHUSTUS: Kindlustusvõtja on kohustatud teavitama kindlustusandjat kõikidest poliisil esitatud andmete muutustest ning muudest teadaolevatest asjaoludest, sh asjaoludest, mis olid kindlustuslepingu sõlmimisel teada, kuid mis jäid tähelepanuta, millel võib olla mõju kindlustusandja otsusele kindlustusleping sõlmida või teha seda kokkulepitud tingimustel. Kõik avaldused, taotlused ja seletused tuleb kindlustusandjale esitada kirjalikku taasesitamist võimaldavas vormis. Kuni andmete muutust kajastava kirjaliku teate saamiseni loeb kindlustusandja õigeks poliisil märgitud andmed.

KINDLUSTUSJÄRELEVALVE: Finantsinspektsioon Sakala 4 15030 Tallinn. Finantsinspektsioon teostab järelevalvet kindlustusandja tegevuse õigusaktidega vastavuse üle. Finantsinspektsioon ei lahenda kindlustusandja ja kindlustusvõtja vahelist lepingulist vaidlust.

MIDA TEHA HAIGESTUMISE VÕI ÕNNETUSJUHTUMI KORRAL: Haigestumise või õnnetusjuhtumi korral palume tasuda raviarvete eest kohapeal ja hiljem esitada need Salva Kindlustusele. Kui Teil ei ole võimalik arveid tasuda, palume sellest tööpäevadel informeerida Salva Kindlustust. Vajadusel väljastame arstile garantiikirja Teie raviarvete tasumise kohta. Puhkepäevadel, öötundidel ja juhul kui Teid määratakse haiglaravile, palume sellest informeerida meditsiiniabi koordinaatorit SOS International, kes korraldab Teie raviarvete tasumise. Haiglaravi korral on SOS Internationali informeerimine kohustuslik. SOS International tel: 0045 38 48 93 20; e-mail: [email protected]

SHORT DESCRIPTION OF COVERAGE IN ENGLISH

This policy gives the following coverage: Policy number: 90028076

Territory covered:

Aland Islands (Finland), Albania, Andorra, Armenia, Azerbaijan, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Cyprus, Denmark, Faroe Islands (Denmark), Finland, France, Georgia, Germany, Gibraltar (UK), Greece, Greenland (Denmark), Hungary, Iceland, Ireland, Isle of Man (UK), Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Moldova, Monaco, Montenegro, Morocco, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Tunisia, Ukraine, United Arab Emirates, United Kingdom, Belarus, Israel, Russia

Validity period: 22.10.2024 00:00 - 25.10.2024 23:59 Insured Persons: Kelli Ilisson, 49502146020 Medical costs: 100,000 EUR Travel interruption: 1,750 EUR Luggage insurance: 400 EUR

Pärnu maantee 16, Tallinn, Estonia, 10141

HOW TO ACT IN CASE OF AN ACCIDENT OR ILLNESS: In case of accident or illness please pay for medical services locally and then submit the invoices to Salva Kindlustus. If You are not able to pay for the medical services please contact Salva Kindlustus in European office hours (from 8:00 to 17:00 UTC+2 hours). If necessary, we will send the doctor a letter of guarantee confirming the coverage of medical treatment costs. On weekends, at night hours and if You are hospitalized, please inform SOS International who will arrange the payment of invoices. Contacting SOS International is obligatory in case of hospitalisation. SOS International tel: 0045 38 48 93 20; e-mail: [email protected]

The coverage of COVID-19 disease in health insurance This policy covers medical treatment costs (costs on diagnosis, medications, hospital treatment) related to COVID-19 disease (including mutations and variations of COVID-19) that incurred abroad up to 200 000 euros. In case the health insurance sum insured specified above in the insurance contract is less than 200 000 euros, the maximum amount of reimbursable COVID-19 medical expenses is limited to health insurance sum insured. In case the Insured is quarantined, extra accommodation and flight ticket costs are covered up to 2000 euros – provided COVID-19 disease of the insured has been medically confirmed.

The coverage of COVID-19 disease in travel interruption We will refund the cost of the unused travel package if the insured person is diagnosed with COVID-19 after the travel cancellation insurance cover comes into effect and therefore travel becomes contraindicated. The insured person must prove COVID-19 disease with a medical certificate, the insurance company does not accept the result of a rapid test as evidence.

КРАТКОЕ ОПИСАНИЕ ЗАЩИТЫ НА РУССКОМ

Данный страховой полис предоставляет следующую защиту: Номер полиса: 90028076

Территория действия:

Аландские острова (Финляндия), Албания, Андорра, Армения, Азербайджан, Австрия, Бельгия, Босния и Герцеговина, Болгария, Хорватия, Чехия, Кипр, Дания, Фарерские острова (Дания), Финляндия, Франция, Грузия, Германия, Гибралтар (Брит.), Греция, Гренландия (Дания), Венгрия, Исландия, Ирландия, Остров Мэн (Великобр.), Италия, Латвия, Лихтенштейн, Литва, Люксембург, Македония, Мальта, Молдавия, Монако, Черногория, Марокко, Нидерланды, Норвегия, Польша, Португалия, Румыния, Сербия, Словакия, Словения, Испания, Швеция, Швейцария, Тунис, Украина, ОАЭ, Великобритания, Белоруссия, Израиль, Россия

Период действия: 22.10.2024 00:00 - 25.10.2024 23:59 Застрахованные лица: Kelli Ilisson, 49502146020 Расходы на лечение: 100 000 EUR Прерывание путешествия: 1 750 EUR Страхование багажа: 400 EUR

Пярнуское шоссе д.16, г. Таллинн, Эстонская Республика, 10141

ЧТО ДЕЛАТЬ В СЛУЧАЕ БОЛЕЗНИ ИЛИ НЕСЧАСТНОГО СЛУЧАЯ:

POLIISI NUMBER: 90028076 VÄLJAANDMISE AEG: 10.10.2024

4/4

ЧТО ДЕЛАТЬ В СЛУЧАЕ БОЛЕЗНИ ИЛИ НЕСЧАСТНОГО СЛУЧАЯ: В случае болезни или несчастного случая оплатите медицинские счета на месте, а затем представьте их Salva Kindlustus. Если вы не можете оплатить счета, сообщите об этом Salva Kindlustus в рабочий день. При необходимости мы вышлем вашему врачу гарантийное письмо в отношении оплаты ваших медицинских счетов. Во время праздников, ночью и в случае госпитализации сообщите об этом координатору оказания медицинской помощи SOS International, который организует оплату ваших медицинских счетов. В случае больничного лечения информирование SOS International является обязательным. SOS International, телефон 0045 38 48 93 20; электронная почта [email protected]

Страхование здоровья в связи с заболеванием COVID-19 На основании страхования здоровья возмещаются понесенные за границей медицинские расходы (расходы на диагностику, лекарства, больничное лечение) в связи с заболеванием COVID-19 (включая мутации и вариации COVID-19) в размере до 200 000 евро. Если указанная в договоре страхования сумма страхования здоровья составляет менее 200 000 евро, максимальный размер возмещаемых в связи с COVID-19 медицинских расходов ограничивается суммой страхования здоровья. Мы также покрываем дополнительные расходы на проживание в случае попадания в карантин, а также, при необходимости, новые билеты домой в размере до 2000 евро при условии, что у застрахованного есть медицинское подтверждение заболевания COVID-19.

Страховая защита от прерывания поездки в связи с заболеванием COVID-19 Мы возместим стоимость неиспользованного туристического пакета, если у застрахованного лица диагностирован COVID-19 после того, как вступает в силу страховая защита от отмены поездки, и поэтому поездка становится противопоказана. Застрахованное лицо должно доказать заболевание COVID-19 с медицинской справкой, страховая компания не принимает в качестве доказательства результат экспресс-теста.

WRIS AS EE NARVA MNT 7D 10117 TALLINN

TALLINN, ESTONIA Tel:+372 6129 130

Email:[email protected]; [email protected]



Emergency Phone 0035924917435

Prepaid Voucher GO23836489-25687336-A(BG)

Scan the QR Code to have our voucher in digital format

Hotel  GARAM LISBOA

Address: Travessa Sacramento a Alcantara 5, Lisbon, PT

Phone: 351-93-1467308

Check-In Date: 22/10/2024 Check-Out Date: 25/10/2024

Room Basis: BB

Number of nights: 3 Rooms: 1

ROOM  Room Type: Room for 1 adult

Category: double or twin room (small room)

Basis: Bed and Breakfast

Names: MISS KELLI ILISSON

supplier Ref.Num: 9053545502321

Only payment for extras to be collected from clients. In case of an issue in real time, please contact the emergency line as per the number above

Important Information 

Important notices to clients, please read carefully:

If you decide to shorten your stay while at a hotel you must obtain from the reception manager on duty his/her signed consent in writing upon your check-out that they will not be charging for unused nights. This is a must requirement and failure to provide such letter will preclude us from seeking any refunds from the hotels/suppliers on your behalf. Refunds from us are strictly subject to hotel providing us with the refund first.

You must report all and any complaints you might have to the hotel on the spot during your stay, immediately as they arise. We will not be liable for any compensation for a problem which could have been rectified during the clients stay, had the hotel been made aware of it.

Remarks  If you fail to check-in for this reservation, or if you cancel or change this reservation after CXL DEADLINE, you may incur penalty charges at the discretion of the hotel of up to 100% of the booking value, unless otherwise stated. THE FRONT DESK IS OPEN DAILY FROM 8:00 AM - 12:30 AM. THIS PROPERTY DOESN'T OFFER AFTER-HOURS CHECK-IN. GUESTS ARRIVING LATE WON'T BE ABLE TO CHECK IN UNTIL THE NEXT MORNING. Bed types are not guaranteed:Double or Twin Room (Small Room) - 2 Twin TwinBed (room for 1 adults .) 12.00 EUR will be paid locally at the hotel(mandatory tax). Know Before You Go:

Children 9 years old and younger are not permitted at this property. Contactless check-out is available.

Fees:

Airport shuttle fee: EUR 35 per vehicle (one-way, maximum occupancy 4) Late check-in fee: EUR 15 for check-in between midnight and 1:00 AM

The above list may not be comprehensive. Fees and deposits may not include tax and are subject to change.

Mandatory Fees and Taxes: You'll be asked to pay the following charges at the property. Fees may include applicable taxes:

A tax is imposed by the city: EUR 4.00 per person, per night, up to 7 nights. This tax does not apply to children under 13 years of age.

We have included all charges provided to us by the property.

Checkin Instructions:

Extra-person charges may apply and vary depending on property policy Government-issued photo identification and a credit card, debit card, or cash deposit may be required at check-in for

incidental charges Special requests are subject to availability upon check-in and may incur additional charges; special requests cannot be

guaranteed This property accepts credit cards, debit cards, and cash Noise-free guestrooms cannot be guaranteed

Special Checkin Instructions: This property offers transfers from the airport (surcharges may apply). Guests must contact the property with arrival details before travel, using the contact information on the booking confirmation. The front desk is open daily from 8:00 AM - midnight. To make arrangements for check-in please contact the property at least 72 hours before arrival using the information on the booking confirmation. If you are planning to arrive after midnight please contact the property in advance using the information on the booking confirmation. Guests will receive an email 72 hours before arrival with check-in instructions. The front desk is staffed during limited hours.

Checkin Time: 3:00 PM

Checkin End Time: midnight

Checkin Minimum Age: 18

Checkout Time: 11:00 AM

Room Name: Double or Twin Room (Small Room)

Room Description: 2 Twin Beds 108 sq feet

Internet - Free WiFi Entertainment - 32-inch flat-screen TV with cable channels Food & Drink - Minibar (fees may apply) Sleep - Blackout drapes/curtains and bed sheets Bathroom - Private bathroom, shower, free toiletries, and towels Practical - Safe, iron/ironing board (on request), and wardrobe or closet Comfort - Daily housekeeping and climate-controlled heating and air conditioning Non-Smoking

Arve nr. 360411-01

Viitenr.: Kliendi nr.: Arve kp.: Maksetähtaeg:

360411165119 16511

10.10.2024 31.10.2024

SOTSIAALKINDLUSTUSAMET PALDISKI MNT 80 TALLINN 15092 ESTONIA

Info: 276367 013 000 001 Tellimuse sisestas: Vivika Rüü tel 6 129 126

REISIJATE NIMED: P1: ILISSON, KELLI(1)

Kood Teenuse kirjeldus, periood Märkused

Hind EUR

Kogus Kokku EUR Käibemaksuta EUR

AB2.LIS (A)

LENNUPILET. 22.10.2024-25.10.2024 TALLINN-LISSABON-TALLINN BN: 105, P: 1

972.99 1 972.99 972.99

HD2.LIS (B)

GO GLOBAL. 22.10.2024-25.10.2024 HOTELL GARAM LISBOA ÜHENE TUBA BN: GO23836489-256873365, P: 1

200.00 3 600.00 600.00

ISU.LIS (C)

SALVA REISIKINDLUSTUS. 22.10.2024-25.10.2024 P: 1

30.18 1 30.18 30.18

Teenused kokku EUR 1603.17 1603.17 Tasuda EUR 1603.17

TEADMISEKS Tutvuge tingimustega: www.wris.ee Arve esitaja jätab endale õiguse arvestada viivist 0.1% päevas, kui raamlepingus ei ole sätestatud teisiti. Viitenumber on maksekorraldusel kohustuslik. Kõik pangalõivud on maksja kulul.

Neto EUR KM% KM EUR Bruto EUR Viide 30.18 ---- 0.00 30.18 Käibemaksuvabastus on rakendatud vastavalt KMS §16(2)1).

***** #40 ***** 1572.99 Erikord vastavuses KMS §40. KM kokku: 0.00 EUR

Pangakontod Swedbank IBAN EE702200221001121372, SWIFT HABAEE2X SEB Pank IBAN EE091010002034102001, SWIFT EEUHEE2X LHV Pank IBAN EE85 7700 7710 0117 9803, SWIFT LHVBEE22

TÄNAME TELLIMUSE EEST!